Pharmacy Question for the Week of April 13, 2020

Pharmacy Compliance Question of the Week


What is the status indicator change for Q5118?


According to the April Outpatient Perspective Payment System updates in Transmittal 10013: “The status indicator for HCPCS code Q5118 (Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg) will be changed retroactively from status indicator =”E2” to status indicator = “K”, Effective January 13, 2020.”

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.